Irinotecan Accord (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is metabolised inside cancer cells to SN‑38, a potent inhibitor of topoisomerase I. By stabilising the topoisomerase‑DNA complex, SN‑38 prevents the re‑ligation of single‑strand DNA breaks, leading to accumulation of DNA damage, inhibition of replication and transcription, and ultimately tumour cell death.

The dose of Irinotecan Accord is individualized and determined by the prescribing oncologist based on factors such as cancer type, treatment protocol, patient weight, renal and hepatic function, and prior therapy. No fixed dosing schedule is provided here; clinicians follow established guidelines and adjust as needed.

Safety data for Irinotecan in pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies the potential risk to the fetus or infant. Breastfeeding is generally not recommended during treatment because the drug can be excreted in milk.

To order Irinotecan Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

The primary alternative to Irinotecan is topotecan, another topoisomerase I inhibitor. While both share a similar mechanism, Irinotecan is often preferred for colorectal and gastric cancers because of its established efficacy in those indications, whereas topotecan is more commonly used in ovarian and small‑cell lung cancers. Toxicity profiles also differ, with Irinotecan causing more severe diarrhea and topotecan being associated with greater myelosuppression.

Irinotecan Accord should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and avoid freezing. Follow standard aseptic handling procedures when preparing the intravenous solution.

Irinotecan Accord is administered by intravenous infusion, usually over 30 to 90 minutes depending on the protocol. The infusion is performed in a clinical setting by qualified healthcare professionals, with appropriate monitoring of vital signs and supportive care measures such as anti‑emetics and hydration.

The most serious adverse events include severe neutropenia (especially febrile neutropenia), life‑threatening diarrhea or colitis that may lead to intestinal perforation, and rare hypersensitivity reactions. Prompt medical evaluation is essential if patients develop fever, persistent diarrhea, abdominal pain, or signs of infection.

Irinotecan Accord is contraindicated in patients with known hypersensitivity to Irinotecan or any of its excipients, those with severe bone‑marrow suppression (e.g., neutrophil count < 500 µL), and individuals with uncontrolled infections. Caution is also advised for patients with significant hepatic impairment or pre‑existing gastrointestinal disorders.